Congestive heart failure calcium channel blockers: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{{Congestive heart failure}} {{CMG}} ==Overview== * Although calcium channel blockers cause vasodilation their overall benefit is minimized by the fact that they have a ...") |
No edit summary |
||
| Line 11: | Line 11: | ||
* [[Dronedarone]] should be avoided in patients who were hospitalized with CHF (this is a boxed warning) | * [[Dronedarone]] should be avoided in patients who were hospitalized with CHF (this is a boxed warning) | ||
* [[Sotalol]] (has a negative inotropic effect) | * [[Sotalol]] (has a negative inotropic effect) | ||
==ACC/AHA Guidelines- Calcium channel blockers (DO NOT EDIT) <ref name="Hunt"> Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202</ref><ref name="pmid19324967">Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19324967 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.] ''Circulation'' 119 (14):1977-2016. [http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192064 DOI:10.1161/CIRCULATIONAHA.109.192064] PMID: [http://pubmed.gov/19324967 19324967]</ref>== | |||
{{cquote| | |||
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]=== | |||
'''1.''' Drugs known to adversely affect the clinical status of patients with current or prior symptoms of [[heart failure]] and reduced [[left ventricular ejection fraction]] ([[LVEF]]) should be avoided or withdrawn whenever possible (e.g., [[NSAID|nonsteroidal anti-inflammatory drugs]], most [[Antiarrhythmic agent|antiarrhythmic drugs]], and most [[Calcium channel blocker|calcium channel blocking drugs]].<ref name="pmid9605782">{{cite journal |author=Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A |title=NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics |journal=[[Archives of Internal Medicine]] |volume=158 |issue=10 |pages=1108–12 |year=1998 |month=May |pmid=9605782 |doi= |url=http://archinte.ama-assn.org/cgi/pmidlookup?view=long&pmid=9605782 |accessdate=2012-04-05}}</ref><ref name="pmid2703968">{{cite journal |author=Herchuelz A, Derenne F, Deger F, Juvent M, Van Ganse E, Staroukine M, Verniory A, Boeynaems JM, Douchamps J |title=Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance |journal=[[The Journal of Pharmacology and Experimental Therapeutics]] |volume=248 |issue=3 |pages=1175–81 |year=1989 |month=March |pmid=2703968 |doi= |url=http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=2703968 |accessdate=2012-04-05}}</ref><ref name="pmid1529943">{{cite journal |author=Gottlieb SS, Robinson S, Krichten CM, Fisher ML |title=Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy |journal=[[The American Journal of Cardiology]] |volume=70 |issue=9 |pages=890–3 |year=1992 |month=October |pmid=1529943 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0002-9149(92)90733-F |accessdate=2012-04-05}}</ref><ref name="pmid1655327">{{cite journal |author=Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE |title=Local forearm vasodilation with intra-arterial administration of enalaprilat in humans |journal=[[Clinical Pharmacology and Therapeutics]] |volume=50 |issue=3 |pages=314–21 |year=1991 |month=September |pmid=1655327 |doi= |url= |accessdate=2012-04-05}}</ref><ref name="pmid2473403">{{cite journal |author= |title=Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators |journal=[[The New England Journal of Medicine]] |volume=321 |issue=6 |pages=406–12 |year=1989 |month=August |pmid=2473403 |doi=10.1056/NEJM198908103210629 |url=http://www.nejm.org/doi/abs/10.1056/NEJM198908103210629?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed |accessdate=2012-04-05}}</ref><ref name="pmid1377359">{{cite journal |author= |title=Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators |journal=[[The New England Journal of Medicine]] |volume=327 |issue=4 |pages=227–33 |year=1992 |month=July |pmid=1377359 |doi=10.1056/NEJM199207233270403 |url=http://dx.doi.org/10.1056/NEJM199207233270403 |accessdate=2012-04-05}}</ref><ref name="pmid2476016">{{cite journal |author=Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB |title=The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio |journal=[[American Heart Journal]] |volume=118 |issue=3 |pages=433–40 |year=1989 |month=September |pmid=2476016 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0002-8703(89)90254-8 |accessdate=2012-04-05}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''}} | |||
==Vote on and Suggest Revisions to the Current Guidelines== | |||
*[[The Living Guidelines: Diagnosis and Management of Chronic Heart Failure | The CHF Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]] | |||
==Guidelines Resources== | |||
*[http://circ.ahajournals.org/content/112/12/e154.full.pdf The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult] <ref name="Hunt"> Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202</ref> | |||
*[http://content.onlinejacc.org/cgi/reprint/53/15/1343.pdf 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation] <ref name="pmid19324967">Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19324967 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.] ''Circulation'' 119 (14):1977-2016. [http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192064 DOI:10.1161/CIRCULATIONAHA.109.192064] PMID: [http://pubmed.gov/19324967 19324967]</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
Revision as of 18:09, 5 April 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
- Although calcium channel blockers cause vasodilation their overall benefit is minimized by the fact that they have a negative inotropic effect and by the reflex activation of the sympathetic nervous system.
- These agents are not recommended as vasodilators in patients with congestive heart failure, however they may be useful as antihypertensive agents in patients with diastolic dysfunction.
Drugs to Avoid in CHF
- Dronedarone should be avoided in patients who were hospitalized with CHF (this is a boxed warning)
- Sotalol (has a negative inotropic effect)
ACC/AHA Guidelines- Calcium channel blockers (DO NOT EDIT) [1][2]
| “ |
Class I1. Drugs known to adversely affect the clinical status of patients with current or prior symptoms of heart failure and reduced left ventricular ejection fraction (LVEF) should be avoided or withdrawn whenever possible (e.g., nonsteroidal anti-inflammatory drugs, most antiarrhythmic drugs, and most calcium channel blocking drugs.[3][4][5][6][7][8][9] (Level of Evidence: B) |
” |
Vote on and Suggest Revisions to the Current Guidelines
Guidelines Resources
- The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [1]
- 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation [2]
References
- ↑ 1.0 1.1 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202
- ↑ 2.0 2.1 Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (14):1977-2016. DOI:10.1161/CIRCULATIONAHA.109.192064 PMID: 19324967
- ↑ Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A (1998). "NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics". Archives of Internal Medicine. 158 (10): 1108–12. PMID 9605782. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ Herchuelz A, Derenne F, Deger F, Juvent M, Van Ganse E, Staroukine M, Verniory A, Boeynaems JM, Douchamps J (1989). "Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance". The Journal of Pharmacology and Experimental Therapeutics. 248 (3): 1175–81. PMID 2703968. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ Gottlieb SS, Robinson S, Krichten CM, Fisher ML (1992). "Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy". The American Journal of Cardiology. 70 (9): 890–3. PMID 1529943. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE (1991). "Local forearm vasodilation with intra-arterial administration of enalaprilat in humans". Clinical Pharmacology and Therapeutics. 50 (3): 314–21. PMID 1655327. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ "Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators". The New England Journal of Medicine. 321 (6): 406–12. 1989. doi:10.1056/NEJM198908103210629. PMID 2473403. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ "Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators". The New England Journal of Medicine. 327 (4): 227–33. 1992. doi:10.1056/NEJM199207233270403. PMID 1377359. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB (1989). "The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio". American Heart Journal. 118 (3): 433–40. PMID 2476016. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help)